GT-20029 is under clinical development by Kintor Pharmaceutical and currently in Phase I for Acne Vulgaris. According to GlobalData, Phase I drugs for Acne Vulgaris have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GT-20029’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GT-20029 overview
GT-20029 is under development for the treatment of androgenetic alopecia and acne vulgaris. It is administered through topical route as gel/tincture form. The drug candidate acts by targeting androgen receptor and cereblon (CRBN). It is being developed based on PROTAC (Protein Degradation Targeting Chimera) technology.
It was under development for androgen sensitive prostate cancer and other androgen receptor related diseases.
Kintor Pharmaceutical overview
Kintor Pharmaceutical (Kintor) is a clinical stage drug company. It is involved in discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases. The company’s lead product candidate Proxalutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Destorsertib (GT0486), GT-1798F, GT20029 and others. It offers therapeutic drugs for various disease such as metastatic castration-resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, urothelial carcinoma, Leukaemia and other disease. Kintor is involved in discovering medicine and drugs for novel diseases such as COVID -19, prostate, breast, blood and liver cancers. In addition it also carries out research and development operations to discover treatment for alopecia and acne. It carters to clients across Taiwan, Hong Kong, the Us, Brazil, and China. The company runs its operations across Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.
For a complete picture of GT-20029’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
